Breath Test Could Predict Mesothelioma Immunotherapy Response
New research shows a breath test called an eNose might help doctors determine which mesothelioma patients are most likely to respond to immunotherapy. Immunotherapy is one of the most promising new approaches to malignant mesothelioma. But not every patient responds. A new Dutch study suggests that biomarkers in a patient’s exhaled breath may be indicators of immunotherapy response. The eNose breath test can identify those biomarkers quickly and easily. The technology might make it easier to decide on the best mesothelioma treatment. Immunotherapy for Malignant Mesothelioma Pleural mesothelioma is a rare but deadly cancer of the lung lining. Until last year, chemotherapy with Alimta (pemetrexed) was the only FDA-approved systemic treatment. In 2020, the FDA approved a combination of immunotherapy…
